References
- Goldberg R. Is there a future for vaccines? Expert Rev. Vaccines1(1), 1–3 (2002).
- Koganty RR. Vaccines: exploiting the role of Toll-like receptors. Expert Rev. Vaccines1(2), 123–124 (2002).
- von Herrath MG. Vaccination to prevent Type 1 diabetes. Expert Rev. Vaccines1(1), 25–28 (2002).
- Bethell D, Pollard AJ. Meningococcal vaccines. Expert Rev. Vaccines1(1), 75–84 (2002).
- Godlee F. Conflicts of interest and pandemic flu. BMJ340, c2947 (2010).
- Boisgérault F, Morón G, Leclerc C. Virus-like particles: a new family of delivery systems. Expert Rev. Vaccines1(1), 101–109 (2002).
- zur Hausen H. HPV vaccines: what remains to be done? Expert Rev. Vaccines10(11), 1505–1507 (2011).
- Chris Elias. The Decade of Vaccines Collaboration: developing a global roadmap for saving lives. Expert Rev. Vaccines10(11), 1493–1495 (2011).
- Poolman JT, Hallander H, Halperin SA. Pertussis vaccines: where to now? Expert Rev. Vaccines10(11), 1497–1500 (2011).
- Ben-Yedidia T, Rudolph W. A universal influenza vaccine: the BiondVax story. Expert Rev. Vaccines10(11), 1509–1512 (2011).
- Cao W, Jin Kim JH, Chirkova T et al. Improving immunogenicity and effectiveness of influenza vaccine in older adults. Expert Rev. Vaccines10(11), 1529–1537 (2011).
- Zhang J, Tarbet EB, Toro H, Tang DC. Adenovirus-vectored drug–vaccine duo as a potential driver for conferring mass protection against infectious diseases. Expert Rev. Vaccines10(11), 1539–1552 (2011).
- Murshid A, Gong J, Stevenson MA, Calderwood SK. Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come. Expert Rev. Vaccines10(11), 1553–1568 (2011).
- Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM. Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev. Vaccines10(11), 1569–1583 (2011).
- Igietseme JU, Eko FO, Black CM. Chlamydia vaccines: recent developments and the role of adjuvants in future formulations. Expert Rev. Vaccines10(11), 1585–1596 (2011).
- Wu X, Smith TG, Rupprecht CE. From brain passage to cell adaptation: the road of human rabies vaccine development. Expert Rev. Vaccines10(11), 1597–1608 (2011).
- Chen LH, Hill DR, Wilder-Smith A. Vaccination of travelers: how far have we come and where are we going? Expert Rev. Vaccines10(11), 1609–1620 (2011).
- Borrow R, Dagan R, Zepp F, Hallander H, Poolman J. Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules. Expert Rev. Vaccines10(11), 1621–1631 (2011).
- Vajo Z. The seasonal influenza vaccine Agriflu®. Expert Rev. Vaccines10(11), 1513–1517 (2011).
- Puig-Barberà J, Pérez-Vilar S, Díez-Domingo J. MF59™-adjuvanted seasonal influenza vaccine in young children. Expert Rev. Vaccines10(11), 1519–1528 (2011).
- Rappuoli R, Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature473, 463–469 (2011).
- Querec TD, Akondy RS, Lee EK et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol.10(1), 116–125 (2009).
Websites
- Teplizumab (Anti-CD3) www.macrogenics.com/products-Teplizumab_CD3.html
- Expert Review of Vaccines News in Brief www.expert-reviews.com/doi/pdf/10.1586/erv.11.100
- Expert Review of Vaccines Special focus issue: Influenza vaccines www.expert-reviews.com/toc/erv/8/4
- Association between Pandemrix and narcolepsy confirmed among Finnish children and adolescents www.thl.fi/en_US/web/en/pressrelease?id=26352